Original Research Article

A study on the use of tacrolimus eye ointment (0.03%) in allergic eye disease

Vasudha Damle1, Prakash Chand Agarwal1,*

1 Dept. of Ophthalmology, RKDF Medical College Hospital & Research Centre, Bhopal, Madhya Pradesh, India

A R T I C L E I N F O

Article history:
Received 05-12-2019
Accepted 14-12-2019
Available online 26-12-2019

Keywords:
Allergic eye disease
Vernal keratoconjunctivitis
Perennial allergic conjunctivitis
Immunomodulators & mast cell stabilizers

A B S T R A C T

Aim: To study the effect of 0.03% tacrolimus eye ointment in allergic eye disease
Materials and Methods: This prospective study was conducted on patients suffering from recurrent allergic eye disease. All those patients who used steroids frequently because of recurrence or chronic refractory cases were included in this study. We included 48 cases in this study. Tacrolimus 0.03% eye ointment was used twice daily for 3 months and effect was seen in terms of improvement in symptoms, signs and any recurrence if occurred after stopping treatment.
Results: Mean age of the patient was 21.04 ±7.02 and mean duration of allergic eye disease was 3.52±0.94. Symptoms and sign scores shown improvement after using tacrolimus eye ointment for 3 months. Itching and redness (88% & 82% respectively) improved dramatically at the end of 1 month. Recurrence was noticed at 6th month follow up in 6 cases after stopping tacrolimus eye ointment so it was restarted. While in 42 cases (87.5%) we didn’t notice any recurrence after stopping tacrolimus eye ointment.
Conclusion: Tacrolimus eye ointment (0.03%) is effective in controlling allergic eye disease and is very effective steroid sparing drug in chronic recurrent cases where frequent use of steroids is required.

© 2019 Published by Innovative Publication. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by/4.0/)

1. Introduction

Presentation of allergic eye disease may vary from seasonal or perennial allergic conjunctivitis to more chronic forms like atopic conjunctivitis or vernal catarrh with involvement of cornea depending upon severity.1 Giant papillary conjunctivitis is not a true allergic disorder.

Seasonal allergic conjunctivitis is usually due to pollens and associated with allergic rhinitis or hay fever while perennial form persists all throughout the year and is usually due to insects or dust. Clinical symptoms and signs are usually bilateral and includes itching, lacrimation, redness, photophobia, lid swelling and foreign body sensation and often associated with running nose.

VKC is a chronic phase of allergic conjunctivitis. Patient presents with common findings pertaining to allergic eye disease like severe itching, watering, burning, photophobia and hyperaemia. Apart from that ropy mucus discharge, conjunctival chemosis, papillary hypertrophy (papillae more than 1mm) also known as cobblestone appearance, gelatinous limbal thickening and Trantas’s dots on bulbar conjunctiva are some hallmark features. In severe cases fibrosis may develop and can cause symblepharon formation. Corneal signs includes punctuate epithelial keratopathy, macroerosion, ring shaped epithelial scarring and shield’s ulcer.

Presentation of VKC in India or tropical countries is relatively different than temperate zones having lesser association with atopy and systemic allergies and significant number of cases present in perennial form.2,3 Atopic kerato conjunctivitis is associated with systemic allergic reaction and usually upper respiratory tract involvement or allergic rhinitis. Lid oedema, excoriation on skin, itching, redness and papillae are commonly seen. Atopic cataracts are also known and not always related to use of steroids.

Pathophysiology in allergic conjunctivitis is not fully understood. In acute phase there is IgE mediated mast cell...
degranuation and followed by release of histamine, tryptase, prostaglandins and leukotrienes leading to itching, watering and chemosis.

VKC is a chronic allergic inflammation of the ocular surface mediated mainly by Th2-lymphocyte and along with histamine; eosinophils, neutrophils, Th2-derived cytokines, chemokines, adhesion molecules, growth factors, fibroblast and lymphocytes are also secreted and found in tears. Giant papillae are due to IL-3 and IL-4.  

Tranta’s dots consists of necrotic eosinophils and epithelial cells. The massive eosinophil infiltration and activation in the conjunctiva is responsible for the corneal complications.

There are various treatment options for allergic conjunctivitis. It includes lubricants, antihistaminics, mast cell stabilizers, immunomodulators (cyclosporine & tacrolimus), mitomycin C, topical steroids and oral steroids in severe cases.

Apart from mast cell stabilizers, antihistaminic drugs like olopatadine, bepotastine besilate and azelastine have dual action. These drugs stabilize mast cells and prevents degranulation and antagonise the action of histamine. Bepotastine inhibit leuotriene B4 and check eosinophil release and so acts as anti-inflammatory drugs.

Steroids are most effective but due to chronicity of disease, complications like cataract and glaucoma can’t be ignored.

Cyclosporine A is steroid sparing drug acting as a immunomodulator. It can be used in concentration of 0.5% to 2% and higher concentration can be prepared by adding cyclosporin injections to artificial tears. It’s use for 7 years duration is being reported.  

Tacrolimus (FK-506) is a macrolide antibiotic derived from (streptomyces tsukubaensis) is a potent immunomodulator. It acts primarily on T-lymphocytes by inhibiting production of cytokines particularly IL-2, checks T-helper-cell mediated B-cell proliferation, inhibits IgE-dependent histamine release from mast cells and basophils. In addition, it also causes a decrease in intracellular adhesion molecules. Both tacrolimus and cyclosporine act on their target cells via cyclophyllin receptors.

Tacrolimus ointment is available in strengths of 0.03% to 0.1%. Conjunctival instillation is associated with irritation so can be applied on skin of eye lids. It’s often used as an alteranative to steroids. Weaning off steroids is reported in 50 to 90% cases in different studies. Literature reports it’s use successfully for 3 years. 

Orally tacrolimus was used in rheumatoid arthritis, psoriasis and also in inflammatory bowel disease. It was also used in patients of corneal grafting.

2. Materials and Methods

This study was conducted in department of Ophthalmology, RKDFMCH&RC. Patients with allergic conjunctivitis with recurrent episodes between the age group of 8 to 30 years were included. This study was conducted from August 2018 to Nov 2019 including 6month follow after stopping tacrolimus eye ointment. We included 48 patients (23 male & 25 females) in this study coming to routine opthalmic OPD and ethical clearance was done. Mean age of the patient was 21.04 ±7.02 and mean duration of disease was 3.52± 0.94.

Detailed history of onset of disease, duration, earlier recurrences, drugs used, association with systemic allergies and history regarding seasonal or perennial nature was taken. Detailed examination done including IOP measurement, fundus and slit lamp examination. We gave prednisolone acetate 1% eye drop for 1 month in acute phase and then at the end of 1 month we switched over to tacrolimus eye ointment 0.03% twice a day for 3 months. Baseline scores were noted before starting tacrolimus 0.03% ointment, then follow up was done every month till 6 months after discontinuing tacrolimus eye ointment. We noted all the symptoms and signs on the day of presentation and then observed if any improvement was there. We looked for any drug intolerance, side effects, whether it was discontinued and if any recurrence was there after withdrawal of tacrolimus. Symptoms and sign scores were taken at baseline, after 1 month, 3months and at 6th month.

2.1. Inclusion criteria

All patients of recurrent allergic conjunctivitis where steroids were required frequently. We included recurrent cases of seasonal and perennial allergic conjunctivitis, VKC and cases of atopic keratoconjunctivitis.

2.2. Exclusion criteria

Refusal for follow up by patients and patient’s on systemic steroids and immunosuppressants

Evaluation was done on the basis of symptoms and signs. We have taken 6 symptoms into account including itching, discharge, lacrimation, photophobia, foreign body sensation
Table 1: Demographic profile

| Age group | No of cases |
|-----------|-------------|
| 1-10 years| 7           |
| 11-20 years| 15         |
| 21-30 years| 26        |
| Sex       |             |
| Male      | 23          |
| Female    | 25          |

Table 2: Different signs were also evaluated and tabulated as follows

| Signs                     | Score | Criteria                                                                 |
|---------------------------|-------|---------------------------------------------------------------------------|
| Palpebral Hyperaemia      | 3     | Impossible to distinguish individual blood vessels                        |
|                           | 2     | Dilatation of many vessels                                                |
|                           | 1     | Dilatation of few vessels                                                 |
|                           | 0     | None                                                                       |
|                           | 3     | Diffuse oedema with opacity                                               |
| Odema                     | 2     | Thinner diffuse oedema                                                    |
|                           | 1     | Slight oedema                                                              |
|                           | 0     | None                                                                       |
|                           | 3     | 20 or more follicles                                                       |
| Follicles                 | 2     | 10 – 19 follicles                                                          |
|                           | 1     | 1 – 9 follicles                                                            |
|                           | 0     | None                                                                       |
| Papillae                  | 3     | Papillae size: 0.6 mm or more                                             |
|                           | 2     | Papillae size: 0.3 – 0.5 mm                                                |
|                           | 1     | Papillae size very small                                                   |
|                           | 0     | None                                                                       |
| Giant papillae >1mm       | 3     | Elevated papillae in 1/2 or more of the upper palpebral conjunctiva        |
|                           | 2     | Elevated papillae in <1/2 of the upper palpebral conjunctiva               |
| Bulbar conjunctiva Hyperaemia | 1 | Flat papillae                                                           |
|                           | 0     | None                                                                       |
|                           | 3     | Elevated papillae in 1/2 or more of the upper palpebral conjunctiva        |
| Odema                     | 2     | Thinner diffuse oedema                                                    |
|                           | 1     | Localized oedema                                                           |
|                           | 0     | None                                                                       |
| Trantas Dots              | 3     | 9 > dots                                                                  |
|                           | 2     | 5-8 dots                                                                  |
|                           | 1     | 1-4 dots                                                                  |
|                           | 0     | None                                                                       |
| Thickening                | 3     | Found in 2/3 or more of the limbal circumference                           |
|                           | 2     | Found in 1/3 to <2/3 of the limbal circumference                           |
|                           | 1     | Found in <1/3 of the limbal circumference                                  |
| Corneal epithelial signs  | 2     | Macrerosions                                                              |
|                           | 1     | Superficial punctate keratitis                                            |
|                           | 0     | None                                                                       |
Table 3: Total subjective symptom score at different visits

| Range of score | No of patients | Min score | Max score | Mean score | Standard deviation |
|---------------|----------------|-----------|-----------|------------|--------------------|
| Baseline 0-18 | 48             | 12        | 17        | 13.39      | 1.36               |
| 1 month 0-18  | 48             | 6         | 15        | 8.06       | 1.39               |
| 3<sup>rd</sup> month 0-18 | 48             | 0         | 8         | 2.70       | 2.02               |
| 6<sup>th</sup> month 0-18 | 48             | 0         | 8         | 1.91       | 1.92               |

Table 4: Total subjective signs score at different visits

| Range of score | No of patients | Min Score | Max Score | Mean score | Standard deviation |
|---------------|----------------|-----------|-----------|------------|--------------------|
| Baseline 0-30 | 48             | 8         | 24        | 15.20      | 5.16               |
| 1 month 0-30  | 48             | 5         | 20        | 10.87      | 4.00               |
| 3<sup>rd</sup> month 0-30 | 48             | 0         | 05        | 1.93       | 1.13               |
| 6<sup>th</sup> month 0-30 | 48             | 0         | 12        | 2.00       | 3.17               |

Fig. 2: Mean sign score showing deviation from baseline after starting tacrolimus 0.03% eye ointment

and redness.

Scoring was done the basis of severity (range 0-18)
0= No symptoms 1= Mild 2= Moderate 3= Severe

Scoring was applied for 10 signs also. Similar grading
pattern followed from 0 to 3.

Range (0-30) 0= No signs 1= Mild 2 = Moderate 3= Severe

All this scoring was done at baseline before starting
tacrolimus, then at 1<sup>st</sup> month, 3<sup>rd</sup> month and 6 months
after starting tacrolimus 0.3%. Mean score calculated and deviation from baseline calculated.

3. Statistical analysis

The collected data was entered in excel sheet. All statistical analysis was carried out using SPSS version20 and appropriate statistical tools were used.

4. Results

Out of 51 patients, 48 patients participated and 3 patients
discontinued ointment use due to irritation. Out of 48 cases, 20 cases were diagnosed with VKC, 23 cases were diagnosed with perennial and seasonal allergies and there were 5 cases of atopic keratoconjunctivitis. At the end of 1 month after giving tacrolimus (0.03%) eye ointment, itching improved in 88% cases, redness improved in 82% cases, FB sensation in 70% cases, watering in 75% cases, discharge in 70% cases and photophobia in 72% cases. Out of 20 cases of VKC, 8 cases (40%) had papillae and has shown improvement at the end of 3 months. Out of 48 cases, conjunctival hyperaemia (palpebral) improved in 80% cases and hyperaemia of bulbar conjunctiva improved in 75% cases. Recurrence was seen in 6 cases on 6<sup>th</sup> month follow up so it was restarted for 1 month and improvement was seen. In 42 cases (87.5%) no recurrence was seen even after 6 months after withdrawal of drug. (Tables 3 and 4) Figures 1 and 2

5. Discussion

In day to day practice we come across patients of allergic
eye disease. Steroids are most effective and then also
because of easy availability, are not used judiciously. Complications like cataract and glaucoma can not be ignored because of prolonged use due to recurrent nature of disease. VKC is mainly seen in younger age group, so recording of IOP is an additional problem.9,10

Tacrolimus is steroid sparing and effective in control
of different allergic eye disease. It’s usefulness in atopic
keratoconjunctivitis is reported in different studies.11,12

Apart from this it’s role in superior limbic conjunctivitis,
refractory VKC, post adenoviral subepithelial infiltrates, has
been reported in literature.13-16

Depending upon the severity of diseases and periodicity
of disease, step ladder approach has been proposed by
Gokhale et al. They also proposed use of tacrolimus or
cyclosporine in moderate or severe cases along with steroids
and antihistaminics.17

Similar effectiveness has been reported with
cyclosporine 2% and 0.1% tacrolimus drops but
cyclosporine drops has to be prepared.18
to tolerate. Only 3 patients discontinued the treatment and were not included further. We used 0.03% ointment on eyelids so tolerance was better.

All the patients included in study were either recurrent cases seasonal or perennial type or refractory cases of VKC. There were 5 cases of atopic conjunctivitis also. All these patients were chronic cases with off and on acute exacerbations and being treated on steroids and antihistaminics frequently though none of them suffered from any complications.

Marked improvement in itching and redness was noticed (88 % and 82%) at the end of one month. Recurrence was seen at 6th month follow up in 6 cases though severity was quite less in comparison to base line values. Tacrolimus 0.3% eye ointment was given for another 1 month and improvement was seen. In 42 cases (87.5%) cases no recurrence was seen even 6months after withdrawal of drug.

6. Conclusion

Tacrolimus 0.03 % eye ointment is a potent steroid sparing drug in recurrent, refractory cases of allergic eye disease so minimising frequent use of steroids.

7. Acknowledgement

I will like to acknowledge Department of Ophthalmology, my seniors, departmental staff and patients for their cooperation.

8. Source of funding

None.

9. Conflict of interest

None.

References

1. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. *J Allergy Clin Immunol*. 2005;115:118–122.
2. Katelaris CH. Ocular allergy in the Asia Pacific region. *Asia Pac Allergy*. 2011;1:108–114.
3. Saboo US, Jain M, Reddy JC, Sangwan VS. Demographic and clinical profile of vernal keratoconjunctivitis at a tertiary eye care center in India. *Indian J Ophthalmol*. 2013;61:486–489.
4. Management of vernal keratoconjunctivitis. *Ophthalmol Ther*. 2013;2(2):73–88.
5. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK 506. *Immunol Today*. 1992;13:136–142.
6. Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. *Cornea*. 2005;24:417–420.
7. Barot RK, Shitole SC, Bhagat N, Patil D, Sawant P, Patil K. Therapeutic effect of 0.1% Tacrolimus Eye Ointment in Allergic Ocular Diseases. *J Clin Diagn Res*. 2016;10(6):5–9.
8. Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, et al. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. *Br J Ophthalmol*. 2014;98(8):1023–1027.
9. Ang M, Se T, Loh R, Farzavandi S, Zhang R, et al. Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitis. *Clin Ophthalmol*. 2012;6:1253–1258.
10. Cinga AK, Cinar Y, Turku FM, Sahinolu-Keskek N, Sahin A, et al. Evaluation of retinal nerve fiber layer thickness in vernal keratoconjunctivitis patients under long-term topical corticosteroid therapy. *Cutan Ocul Toxicol*. 2014;33(3):184–188.
11. Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharocconjunctivitis: a retrospective study. *Acta Ophthalmol Scand*. 2006;84(5):693–695.
12. Zribi H, Descamps V, Hoang-Xuan T, Crickx B, Doan S. Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids. *J Oto Acad Dermatol Venereol*. 2009;23(4):489–490.
13. Ghanem RC, Vargas JF, Ghanem VC. Tacrolimus for the treatment of subepithelial infiltrates resistant to topical steroids after adenoviral keratoconjunctivitis. *Cornea*. 2014;33(11):1210–1213.
14. Kymionis GD, Klados NE, Kontadakis GA, Mikropoulos DG. Treatment of superior limbic keratoconjunctivitis with topical tacrolimus 0.03% ointment. *Cornea*. 2013;32(11):1499–1501.
15. Chatterjee S, Agrawal D. Tacrolimus in Corticosteroid- Refractory Vernal Keratoconjunctivitis. *Cornea*. 2016;.
16. Erdenest N, Solomon A. Topical immunomodulators in the management of allergic eye diseases. *Curr Opin Allergy Clin Immunol*. 2014;14(5):457–463.
17. Gokhale NS. Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm. *Indian J Ophthalmol*. 2016;64(2):145–148.
18. Labhabaroenwongs P, Irapongsanamanruk O, Visitsunthorn N, Kosrirukwongs P, Saengin P, Vichyanond P. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. *Asian Pac J Allergy Immunol*. 2012;30:177–184.

Author biography

Vasudha Damle Associate Professor

Prakash Chand Agarwal Professor and HOD

Cite this article: Damle V, Agarwal PC. A study on the use of tacrolimus eye ointment (0.03%) in allergic eye disease. *Int J Ocul Oncol Oculoplasty*. 2019;5(4):259-263.